



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

14<sup>th</sup> February 2025

To,

**BSE LIMITED**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sirs,

**Subject: Media release: Q3 of 2024-25**

Please find enclosed a press release issued by the Company in respect of financial results for the quarter ended 31<sup>st</sup> December 2024.

This is for your information and record.

Yours faithfully  
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151



## **GlaxoSmithKline Pharmaceuticals Limited (GSK) Delivers Strong Q3 Performance with Double-Digit Growth**

**Mumbai, India** – GlaxoSmithKline Pharmaceuticals Ltd (GSK) announced its financial results for the third quarter ended December 31, 2024, demonstrating strong growth and sustained profitability. The company reported a 18% increase in revenue from operations, reaching INR 946 crores while achieving a Profit After Tax (PAT) of INR 229 crores.

The quarter saw strong performance across key product portfolios. Flagship brands within the general medicines portfolio including *Augmentin*, *Ceftum*, and *T-bact* strengthened their market positions with share gains. The company's innovative Respiratory portfolio, led by *Nucala* and *Trelegy*, achieved robust growth, further expanding patient access across India.

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines. The adult vaccines division continues to gain momentum with *Shingrix* (Herpes Zoster Vaccine – recombinant, adjuvanted), as the company spearheads the expansion of adult immunisation in India.

Commenting on the results, **Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited**, said, “Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, we continue to strengthen our market presence while ensuring broader access to our medicines and vaccines.”

**About GlaxoSmithKline Pharmaceuticals Limited:** GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit [GSK-India.com](https://www.gsk-india.com).

### **Media Contact**

Ransom D'Souza – [ransom.a.dsouza@gsk.com](mailto:ransom.a.dsouza@gsk.com)

**Communications & Government Affairs**